Drugs / Inarigivir soproxil
Inarigivir soproxil
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01803308 | Mar 2013 → Aug 2014 | chronic hepatitis C virus infection | Syneos Health | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04059198 | Oct 2019 → Apr 2020 | chronic hepatitis B virus infection | F-star Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04023721 | Jun 2019 → Jul 2020 | chronic hepatitis B virus infection | F-star Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03932513 | Apr → Dec 2019 | chronic hepatitis B virus infection | F-star Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03434353 | Feb 2018 → Jan 2020 | chronic hepatitis B virus infection | Gilead Sciences | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02751996 Comparator | May 2016 → Feb 2020 | hepatitis B virus infection | F-star Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inarigivir soproxil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023721 ↗ |
| Known as | Inarigivir soproxilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1076930 ↗ |
| Known as | SB 9200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02751996 ↗ |
| Known as | SB-44 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1076930 ↗ |
| Modality | Small molecule | — CHEMBL1076930 ↗ |
| Route | Oral | “Administered orally once daily one hour before or one hour after a meal” NCT03434353 ↗ |